Surgery Partners (SGRY) Projected to Post Earnings on Monday

Surgery Partners (NASDAQ:SGRY) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Surgery Partners to post earnings of $0.08 per share and revenue of $777.77 million for the quarter. Surgery Partners has set its FY 2025 guidance at EPS.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.01. The company had revenue of $864.40 million for the quarter, compared to analyst estimates of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. On average, analysts expect Surgery Partners to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surgery Partners Price Performance

Surgery Partners stock opened at $22.20 on Friday. The business has a 50 day simple moving average of $22.61 and a 200 day simple moving average of $23.48. Surgery Partners has a one year low of $19.50 and a one year high of $33.97. The company has a market capitalization of $2.85 billion, a PE ratio of -46.25, a price-to-earnings-growth ratio of 19.21 and a beta of 1.96. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66.

Analyst Ratings Changes

Several equities research analysts have recently commented on SGRY shares. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 target price on shares of Surgery Partners in a research note on Tuesday, March 25th. Macquarie decreased their price objective on shares of Surgery Partners from $34.00 to $33.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 11th. Finally, Benchmark reaffirmed a “buy” rating and set a $35.00 price objective on shares of Surgery Partners in a report on Monday, April 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.75.

Insider Activity

In other Surgery Partners news, CFO David T. Doherty sold 6,733 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $24.02, for a total value of $161,726.66. Following the transaction, the chief financial officer now directly owns 150,868 shares of the company’s stock, valued at approximately $3,623,849.36. This trade represents a 4.27 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $24.09, for a total transaction of $76,028.04. Following the sale, the insider now owns 63,408 shares of the company’s stock, valued at $1,527,498.72. The trade was a 4.74 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.30% of the company’s stock.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.